Home > About Us > News & Events

News

June 2, 2017 - NovaDigm Therapeutics Awarded $6 Million by U.S. Department of Defense to Conduct a Phase 2a Staphylococcus aureus Vaccine Trial

 Click here for complete story

August 15, 2016 - NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women With Recurrent Vulvovaginal Candidiasis (RVVC)

 Click here for complete story

November 3, 2015 - NovaDigm Therapeutics’ Chief Executive Officer, Timothy Cooke, Appointed to the National Vaccine Advisory Committee

  Click here for complete story

June 10, 2014 - NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions

 Click here for complete story

October 3, 2013 - NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine Against Candida
 Click here for complete story

September 26, 2013 - NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC)
 Click here for complete story

December 13, 2012 - Results from Positive Phase 1 Study of NovaDigm Therapeutics’ NDV-3 Vaccine for Candida and Staph Infections Published in Vaccine
 Click here for complete story

May 7, 2012 - NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
 Click here for complete story

Sep 26, 2011 - "NovaDigm Unveils Data with Dual Fungal/Bacterial Vaccine" – BioWorld Today Article
 Click here for complete story

Sep 19, 2011 - NovaDigm Therapeutics Presents Positive Phase 1 Safety and Immunogenicity Data for NDV-3 Vaccine
 Click here for complete story

Sep 19, 2011 - NovaDigm Therapeutics Presents Positive Preclinical Data in Vulvovaginal Candidiasis for NDV-3 Vaccine
 Click here for complete story

Dec 3, 2009 - R. Gordon Douglas, Jr., appointed Chairman of the Board.
 Click here for complete story